At a glance
- Originator SICOR
- Class Analgesics; Anti-inflammatories; Antibacterials; Small molecules
- Mechanism of Action Adenosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation; Pain; Septic shock
Most Recent Events
- 11 May 1998 Discontinued-Preclinical for Inflammation in USA (unspecified route)
- 11 May 1998 No-Development-Reported for Pain in USA (unspecified route)
- 07 Jun 1995 Preclinical development for Inflammation in USA (unspecified route)